The Iga Nephropathy Drugs Market is entering a transformative phase as the first targeted therapies receive regulatory approval and the therapeutic landscape shifts from supportive care to disease-modifying treatment. IgA nephropathy, also known as Berger's disease, is the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage renal failure....